These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens]. Nakashio S; Iwasawa H; Iino S; Shimada J Jpn J Antibiot; 1997 Oct; 50(10):844-53. PubMed ID: 9412874 [TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria. Brumfitt W; Hamilton-Miller JM; Shah S J Antimicrob Chemother; 1992 Jul; 30 Suppl A():29-37. PubMed ID: 1399948 [TBL] [Abstract][Full Text] [Related]
6. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Pankuch GA; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 1994 Sep; 38(9):2065-72. PubMed ID: 7811020 [TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study. Sader HS; Jones RN; Ballow CH; Biedenbach DJ; Cered RF; Braz J Infect Dis; 2001 Feb; 5(1):21-31. PubMed ID: 11290311 [TBL] [Abstract][Full Text] [Related]
8. In vitro activities of a new ketolide, ABT-773, against multidrug-resistant gram-positive cocci. Singh KV; Malathum K; Murray BE Antimicrob Agents Chemother; 2001 Dec; 45(12):3640-3. PubMed ID: 11709359 [TBL] [Abstract][Full Text] [Related]
9. Susceptibility to RPR 106,972, quinupristin/dalfopristin and erythromycin among recent clinical isolates of enterococci, staphylococci and streptococci from North American medical centres. Barry AL; Fuchs PC; Brown SD J Antimicrob Chemother; 1998 Nov; 42(5):651-5. PubMed ID: 9848451 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of quinupristin/dalfopristin, RP59500, against gram-positive clinical isolates. Qadri SM; Ueno Y; Abu Mostafa FM; Halim M Chemotherapy; 1997; 43(2):94-9. PubMed ID: 9084917 [TBL] [Abstract][Full Text] [Related]
11. Activities of clindamycin, synercid, telithromycin, linezolid, and mupirocin against Gram-positive coccal strains resistant to erythromycin in Korea. Kwon AR; Yoon EJ; Yoon JM; Kim H; Shim MJ; Choi EC Arch Pharm Res; 2007 Jul; 30(7):840-3. PubMed ID: 17703735 [TBL] [Abstract][Full Text] [Related]
12. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Entenza JM; Drugeon H; Glauser MP; Moreillon P Antimicrob Agents Chemother; 1995 Jul; 39(7):1419-24. PubMed ID: 7492078 [TBL] [Abstract][Full Text] [Related]
13. Comparative in-vitro activity of ketolide HMR 3647 and four macrolides against gram-positive cocci of known erythromycin susceptibility status. Hamilton-Miller JM; Shah S J Antimicrob Chemother; 1998 Jun; 41(6):649-53. PubMed ID: 9687104 [TBL] [Abstract][Full Text] [Related]
14. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci. Coque TM; Singh KV; Murray BE J Antimicrob Chemother; 1996 May; 37(5):1011-6. PubMed ID: 8737152 [TBL] [Abstract][Full Text] [Related]
15. Comparative in-vitro activity of erythromycin, vancomycin and pristinamycin. Maskell JP; Sefton AM; Yong J; Chi SJ; Williams JD Infection; 1988; 16(6):365-70. PubMed ID: 3146552 [TBL] [Abstract][Full Text] [Related]
16. The in-vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, alone and in combination. Neu HC; Chin NX; Gu JW J Antimicrob Chemother; 1992 Jul; 30 Suppl A():83-94. PubMed ID: 1328138 [TBL] [Abstract][Full Text] [Related]
17. In-vitro activities of 14-, 15- and 16-membered macrolides against gram-positive cocci. Hamilton-Miller JM J Antimicrob Chemother; 1992 Feb; 29(2):141-7. PubMed ID: 1506329 [TBL] [Abstract][Full Text] [Related]
18. In-vitro activity of RP 59500, a new synergic antibacterial agent, against Legionella spp. Dubois J; Joly JR J Antimicrob Chemother; 1992 Jul; 30 Suppl A():77-81. PubMed ID: 1399954 [TBL] [Abstract][Full Text] [Related]
19. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin. Spangler SK; Jacobs MR; Appelbaum PC Antimicrob Agents Chemother; 1992 Apr; 36(4):856-9. PubMed ID: 1323956 [TBL] [Abstract][Full Text] [Related]
20. In-vitro activity of RP 59500, a semisynthetic streptogramin, against staphylococci and streptococci. Pechère JC J Antimicrob Chemother; 1992 Jul; 30 Suppl A():15-8. PubMed ID: 1399945 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]